1. Home
  2. IMNM vs NEO Comparison

IMNM vs NEO Comparison

Compare IMNM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNM
  • NEO
  • Stock Information
  • Founded
  • IMNM 2006
  • NEO 2001
  • Country
  • IMNM United States
  • NEO United States
  • Employees
  • IMNM N/A
  • NEO N/A
  • Industry
  • IMNM Medicinal Chemicals and Botanical Products
  • NEO Precision Instruments
  • Sector
  • IMNM Health Care
  • NEO Health Care
  • Exchange
  • IMNM Nasdaq
  • NEO Nasdaq
  • Market Cap
  • IMNM 1.2B
  • NEO 1.2B
  • IPO Year
  • IMNM 2020
  • NEO 1999
  • Fundamental
  • Price
  • IMNM $18.12
  • NEO $10.20
  • Analyst Decision
  • IMNM Strong Buy
  • NEO Buy
  • Analyst Count
  • IMNM 8
  • NEO 10
  • Target Price
  • IMNM $25.75
  • NEO $12.56
  • AVG Volume (30 Days)
  • IMNM 1.4M
  • NEO 3.2M
  • Earning Date
  • IMNM 11-06-2025
  • NEO 10-28-2025
  • Dividend Yield
  • IMNM N/A
  • NEO N/A
  • EPS Growth
  • IMNM N/A
  • NEO N/A
  • EPS
  • IMNM N/A
  • NEO N/A
  • Revenue
  • IMNM $9,679,000.00
  • NEO $709,162,000.00
  • Revenue This Year
  • IMNM N/A
  • NEO $10.74
  • Revenue Next Year
  • IMNM $85.36
  • NEO $9.85
  • P/E Ratio
  • IMNM N/A
  • NEO N/A
  • Revenue Growth
  • IMNM N/A
  • NEO 10.10
  • 52 Week Low
  • IMNM $5.15
  • NEO $4.72
  • 52 Week High
  • IMNM $18.79
  • NEO $19.12
  • Technical
  • Relative Strength Index (RSI)
  • IMNM 64.32
  • NEO 54.74
  • Support Level
  • IMNM $16.11
  • NEO $9.78
  • Resistance Level
  • IMNM $17.94
  • NEO $10.44
  • Average True Range (ATR)
  • IMNM 1.26
  • NEO 0.54
  • MACD
  • IMNM 0.02
  • NEO -0.07
  • Stochastic Oscillator
  • IMNM 86.56
  • NEO 57.96

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: